Frequently asked questions

CANLYTx is a comprehensive Whole Exome based Genomic test that examines your tumor DNA to uncover the complex genomic alterations that cause your cancer. It identifies tumor specific molecular signatures and mutation profiles. The test reports the overall TMB from 23,000 genes, and somatic alterations like SNVs, indels and copy number alterations for 2500 genes.

Whole Exome is the functional part of the genome that is responsible for the normal functioning of the human body. It comprises circa 23,000 genes performing different functions. Analysis of this whole exome allows detection of various genomic alterations directly or indirectly responsible for cancer and also responses to therapy/treatment. Single gene/hotspot/comprehensive panel is the analysis of a specific set of genes. This type of targeted or specific analysis cannot detect the latest or novel and rare genomic alterations that may be the causative factor of your cancer or your response to therapy.

MEDLYTx is a pharmacogenomics test that offers a custom targeted whole exome analysis of your DNA. It identifies biomarkers to predict how you might respond to various medications. This test covers 250 drugs used in oncology, pain management, cardiology, endocrinology, and other medical conditions, providing comprehensive report. By doing so, it helps avoid adverse drug reactions and improves drug efficacy for better health outcomes.

This test identifies genetic variations that influence drug metabolism and effectiveness, enabling healthcare providers to customize medication choices and dosages based on your metabolization profile. This personalized approach reduces the risk of adverse drug reactions, enhances treatment outcomes, and ensures more effective and safer medication management.

Whole Exome Sequencing (WES), is performed in the Genomics laboratory located in California, USA our partner labs for Next Generation Sequencing (NGS) services. This laboratory is CAP and CLIA certified.

Cancer:
Formalin-fixed paraffin embedded (FFPE) specimens*
**Whole Peripheral Blood (when no tissue sample is available)
*subject to fulfilling the criteria
** TAT & cost will vary
Wellness:
Whole Peripheral Blood

Test can be ordered by writing to us at info@kyvorgenomics.com
or call-in:
Inside India: +91 93083 93083
Outside India: +1 (302) 504 8088

• Histopathology report
• Pathology report
• Clinical diagnosis & summary
• If currently out patient, the last clinical discharge summary
• Kyvor patient consent form and patient information signed by the patient or the patient’s care taker
• A list of medications used

Our estimated turn-around-time is 4-5 weeks once samples are available in the laboratory.

The combination of different sciences involved in the analysis, and complexity of the data being analysed requires stringent Quality Control and Quality Assurance processes to be complied with to ensure the accuracy of the findings.

For further information on the test or for questions on the results of the test please contact: info@kyvorgenomics.com

The cost of the test will be shared when you get in touch with us. Accepted modes of payment is online or cheque, details of which will be shared with you based on your location. If your doctor recommends the test, some insurance providers will reimburse the cost of the test. For specific locations, we have EMI options available and you can check with us on info@kyvorgenomics.com for availability in your location.

All Solid tumours, for example Breast, Lung, Colorectal, Head and Neck to mention a few.

Screening tests are crucial if you have a family history of cancer or inherited diseases. Early detection significantly improves survival rates and often requires less aggressive interventions. Inherited genetic mutations can increase your cancer risk, making regular screenings essential. Discussing your family history with a healthcare provider can help you determine the most appropriate tests and frequency. Consider getting a Hereditary Genetic test if you want to identify genetic predispositions before symptoms appear, allowing for proactive health management.

The frequency of genetic testing varies based on the type of test and individual health conditions: Hereditary Genetic Testing and MEDLYTx:

• -These tests analyze inherited genes.
• -They are typically one-time tests providing lifelong insights.
• -Hereditary testing identifies genetic variations you inherit.
• -MEDLYTx examines markers to predict your response to medications.

Somatic Testing (e.g., CANLYTx):

• -The frequency depends on the diagnostic stage, surgical procedures, and treatment plans.
• -Consult your healthcare provider for personalized recommendations.

Every patient has unique genomic alterations and therefore the results will vary from patient to patient. The test will match your genomic alterations and categorize the suitable therapy . CANLYTx matches your specific genetic changes to identify suitable therapies that are guideline approved, including immunotherapy options, off-label treatments relevant case studied and clinical trials based on your genetic profile.

Consider taking a MEDLYTx test if you've been on long-term medications or undergoing chemotherapy. For instance, if you're on cardiovascular drugs or antidepressants without noticeable improvement, this genetic test can reveal how your body processes these medications, enabling a personalized treatment plan for better health outcomes.

Somatic mutations are acquired in a person's lifetime, often leading to cancers while germline mutations are inherited and present in every cell of the body. CANLYTx primarily identifies somatic mutations. In case of suspected germline mutation, sequencing the patient's normal sample is recommended.

No two cancers are alike and No two treatments are alike. The differences in cancers is due to the unique genetic characteristics. Cancer can be from the same organ, but no two cancers are alike. Similarly, due to genetic differences, no two treatments can be identical, as each person responds differently to each treatment.

Liquid biopsy offers several key benefits for cancer management:
1. Analysis of circulating tumor DNA (ctDNA) can be performed for real-time monitoring of response to treatment, providing a guided approach for neoadjuvant and adjuvant therapy.
2. Detectable ctDNA after surgery and/or completion of adjuvant therapy is strongly associated with a high risk of disease recurrence, suggesting that ctDNA is a robust marker for minimal residual disease (MRD).
3. Liquid biopsy allows identification, tracking, and quantification of tumor clones bearing distinct genetic alterations. Emergence of resistance mutations can be detected early.
By providing a minimally invasive window into the tumor's molecular profile, liquid biopsy enables dynamic monitoring of disease burden and evolution during treatment. This information can guide therapy selection and identify emerging resistance to optimize patient outcomes

While CANLYTx and MEDLYTx primarily focus on treatment recommendations, other tests like NUTRILYTx can provide insights into personalized nutrition and lifestyle changes based on genetic predispositions. Consulting with a genetic counselor or healthcare provider can offer tailored advice.

Consider getting a NUTRILYTx test if you want to enhance your overall health by identifying optimal nutrient intake tailored to your genetic makeup. This test offers lifelong insights into how your genes impact health, guiding targeted nutrient optimization through personalized supplement recommendations and diet plans.

While the tests are designed to provide comprehensive analysis, you can discuss specific concerns or focus areas with your healthcare provider or the Kyvor Genomics team to ensure the test meets your needs.

Yes, genomic testing can be performed on pediatric patients to identify genetic conditions, understand disease risks, and tailor treatments. It is essential to consult with a healthcare provider to determine the appropriateness of testing for a child.

Genomic testing itself carries minimal physical risk, as it typically involves a blood draw or tissue sample. However, there may be psychological or emotional impacts from learning about potential genetic risks. Genetic counseling is available to help manage these aspects.

NGS allows for the simultaneous sequencing of millions of DNA fragments, providing a more comprehensive and faster analysis compared to traditional sequencing methods, which sequence DNA one fragment at a time.

AI and advanced bioinformatics tools are used to analyze large datasets, identify patterns, and generate insights from genomic data. This helps in providing accurate, efficient, and actionable results for personalized treatment planning.

Genetic counseling is a process to help individuals, couples, and families understand their risk of an inherited genetic condition to make informed health decisions. Healthcare professionals called ‘Genetic Counselors’, with training in medical genetics and counselling provide genetic counselling consultations.

• Inform you about genetic conditions and how they are inherited within your family
• Assess the risk of genetic diseases for you or your family
• Explain genetic testing and suggest it if necessary
• Help you interpret your genetic test results
• Offer support throughout the entire process